文献速递神经肿瘤

放疗后顶盖胶质瘤症状性假性进展予贝伐珠单抗挽救:病例报告与文献综述

Rescue bevacizumab following symptomatic pseudoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature.
PubMed 文献 · J Neurooncol · 2019-05-03

本文报告一名20岁男性活检证实的顶盖低级别星形细胞瘤患者,在接受total dose 54 Gy/30次调强立体定向放疗后6周出现头痛、乏力及视力恶化,伴影像学加重,诊断为假性进展;地塞米松试验获益有限后,予四周期贝伐珠单抗,临床与影像迅速改善。文献综述聚焦贝伐珠单抗治疗CNS肿瘤放疗后症状性假性进展。

要点

  • 放疗后假性进展可模仿肿瘤进展,需与放疗坏死区分。
  • 该例地塞米松获益有限后,贝伐珠单抗四周期获快速临床与影像改善。
  • 贝伐珠单抗或可作为症状性假性进展的挽救治疗选择。

核心结论

  • 研究结果支持贝伐珠单抗作为症状性假性进展挽救药物的潜在用途。

研究设计与样本

  • 病例报告:一名20岁男性活检证实的顶盖低级别星形细胞瘤患者。
  • 并针对贝伐珠单抗治疗CNS肿瘤放疗后症状性假性进展进行文献综述。

主要发现

  • 患者接受total dose 54 Gy、30次每日分割的调强立体定向放疗。
  • 放疗后6周出现进行性头痛、乏力及视力恶化,伴影像学表现加重。
  • 诊断为假性进展,地塞米松试验获益有限后予四周期贝伐珠单抗,临床与影像迅速改善。

关键数值与推荐

  • 放疗剂量为total dose 54 Gy,30次每日分割。
  • 贝伐珠单抗共四周期。

临床怎么用

  • 对CNS肿瘤放疗后出现症状性假性进展且地塞米松获益有限者,可考虑贝伐珠单抗挽救治疗。

局限性

  • 本文为单例病例报告并附文献综述,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced pseudoprogression is a subacute clinical entity that is distinct from radiation necrosis and mimics tumor progression. Bevacizumab is a well-described treatment option for radiation necrosis, but its role in pseudoprogression is not clearly defined. METHODS: We report a case of radiation-induced pseudoprogression rescued with bevacizumab in a 20-year-old man with a biopsy-proven low-grade astrocytoma of the tectum. A review of the literature was also conducted specific to bevacizumab as a treatment for symptomatic pseudoprogression after radiotherapy for CNS tumors. RESULTS: This patient was treated with definitive intensity modulated stereotactic radiotherapy at a total dose of 54 Gy delivered in 30 daily fractions. Six weeks after radiotherapy the patient developed progressive headache, weakness and a documented deterioration in vision, which was accompanied by worsening of radiographic findings. A diagnosis of pseudoprogression was made and after limited benefit from a trial of dexamethasone, four cycles of bevacizumab were administered which resulted in rapid clinical and radiographic improvement. CONCLUSIONS: Our findings support the potential use of bevacizumab as a rescue agent for symptomatic pseudoprogression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nguyen TK, Perry J, Sundaram ANE, et al. Rescue bevacizumab following symptomatic pseudoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature. J Neurooncol. 2019. PMID: 31054097. doi:10.1007/s11060-019-03179-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。